New combo aims to clear leukemia before transplant

NCT ID NCT07443488

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining olverembatinib (a targeted pill) with inotuzumab ozogamicin (an antibody-drug conjugate) can clear remaining leukemia cells in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who still have detectable disease after initial chemotherapy. The goal is to get patients into deep remission so they can proceed to a stem cell transplant. The study will enroll 20 participants and measure how many achieve minimal residual disease (MRD) negativity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olverembatinib and inotuzumab ozogamicin
What this could lead to: If successful, this combination could help more patients with Ph+ ALL achieve deep remission and successfully receive a stem cell transplant, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination may cause side effects, and it is not yet known if it will improve survival or cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HSCT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia, acute lymphocytic, susceptibility to, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HSCT PH+ ALL

More trials for these conditions

Other studies related to the condition(s) this trial covers.